Author:
Kinoshita Toshihiko,Bai Ya-Mei,Kim Jong-Hoon,Miyake Mutsuo,Oshima Nobuyuki
Funder
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.
Meiji Seika Pharma Co., Ltd.
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Abi-Dargham A (2014) Schizophrenia: overview and dopamine dysfunction. J Clin Psychiatry 75:e31
2. American Psychiatric Association (2000) Diagnostic and Stastical Manual of Mental Disorders: DSM-IV-TR. Washington, DC.
3. Citrome L (2014a) Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 10:893–903
4. Citrome L (2014b) Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf 13:803–830
5. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU (2012) Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26:733–759
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献